Gilead & MicroDose Ink RSV Deal
Gilead Sciences said Wednesday it signed a licensing deal with MicroDose Therapeutx for an experimental respiratory syncytial virus treatment.
Gilead Sciences and MicroDose Therapeutx have inked an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose’s inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).
According to the agreement, MicroDose will receive an upfront payment and research funding to support development of MDT-637 through Phase IIa trials, after which Gilead can assume full development responsibility. MicroDose is also eligible to receive additional payments based upon the achievement of certain development, regulatory and commercial milestones, as well as development fees and royalties on potential sales.
"This strategic collaboration is a significant milestone i
Related News
-
News How can pharma achieve ‘Net Zero’? Through driving change in pharma manufacturing
Through the entire product lifecycle – production, consumption and disposal – the pharma industry significantly impacts the environment. -
News Planning for supply chain resilience
Engagement-based strategy could increase resilience of pharma supply chain. -
News Strategies for managing an outsourcing partner
Robust oversight linked to increased efficiency and better communication with outsourcing partners. -
News Updated: CPHI North America 2022 Blog
Follow along for live updates from CPHI North America, taking place in Philadelphia, PA from May 17-19. -
News Greater standardisation needed for effective ESG reporting - Expert panel
Increased transparency and standardisation in ESG reporting frameworks is emerging as a key requirement for investors. -
News MedPharm: Increased investment driving developments in topical drugs market
We caught up with MedPharm at CPHI North America to discuss opportunities in the topical and transdermal products space. -
News Pharmapack Awards 2022: Winners Revealed
The jury assessed a wide range of industry-changing innovations in packaging and drug delivery, ultimately selecting seven winners. -
News What it means to be 'At the heart of Pharma'
Informa Markets colleagues explain the motivations behind CPHI’s rebrand.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance